A study looking at HSV1716 to treat mesothelioma

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:





Phase 1/2

This study is looking at HSV1716 to treat people with mesothelioma of the chest.

More about this trial

Doctors treat mesothelioma with surgery, radiotherapy or chemotherapy. Unfortunately these don’t always work and so they are looking for new ways to treat mesothelioma.

HSV1716 is a type of virus that infects cancer cells and kills them. We know from laboratory studies Open a glossary item that HSV1716 gets into mesothelioma cells and can help kill them. We also know from other clinical trials that it is safe and may help people with other types of cancer.

The aim of this study is to find out how safe HSV1716 is to treat people with mesothelioma of the chest.

Who can enter

You may be able to enter this study if you

  • Have mesothelioma of the chest (pleural mesothelioma) and can’t have surgery to remove it
  • Have a collection of fluid between the sheets of skin which cover the lungs (pleural effusion) and have a tube in place to drain the fluid or need to have a tube put in
  • Have satisfactory blood test results
  • Are well enough to be up and about for at least half the day (performance status 0, 1, or 2)
  • Are willing to take reliable contraception if you or your partner could become pregnant
  • Are at least 18 years old

You cannot enter this study if

  • You may need to have radiotherapy or chemotherapy to relieve symptoms (palliative treatment Open a glossary item) in the next month
  • You have had a treatment similar to HSV1716 before – your doctor can advise
  • You have had an experimental drug as part of a clinical trial in the last 2 months
  • You are taking more than 5mg of prednisolone a day
  • You have had another cancer in the last 5 years apart from basal cell skin cancer or in situ carcinoma of the cervix
  • You have a medical condition that is a cause for concern or could affect you taking part in this trial
  • The tube you have in place to drain the fluid between the sheets of skin covering your lungs isn’t a type suitable for use in this trial – your doctor can advise about this
  • You are pregnant or breastfeeding

Trial design

This is a phase 1/2 study. It is in 2 parts. Part A will recruit 3 people. Part B will recruit up to 9 people. Everyone will have HSV1716.

People in part 1 have 1 dose of HSV1716. If they don’t have serious side effects then the study will go on to part B.

The first 3 people in part B will have 2 doses of HSV1716. If they don’t have serious side effects the next 6 will have 4 doses. You have 1 dose a week.

HSV1716 is in liquid form and will be pushed into the space around your lungs by putting it into the tube that is used to drain away excess fluid.

Hospital visits

You see the doctor to have some tests before taking part in this study. These tests include

  • A physical examination
  • Blood tests
  • Urine test
  • Taking a sample of fluid from the tube in your chest
  • Mouth swab
  • Heart trace (ECG Open a glossary item)
  • Chest X-ray
  • CT scan

During treatment you see the doctor regularly to have the same tests apart from the heart trace, chest X-ray and CT scan.

You have a CT scan a month and 2 months after starting treatment.

After treatment you see the doctor every month until HSV1716 can’t be found in the sample of fluid taken from the tube in your chest.

Side effects

This is the first time HSV1716 has been used to treat mesothelioma. So there may be side effects we don’t know about. Side effects may include

  • Flu like symptoms
  • Inflammation Open a glossary item of the lining of the lung
  • Lung infection
  • Infection where the tube enters your chest

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Prof Penella Woll

Supported by

Experimental Cancer Medicine Centre (ECMC)
Sheffield Teaching Hospitals NHS Foundation Trust
VIRTTU Biologics

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page